Skip to main content

Day: August 5, 2022

Correction: Form 8.3 – Emis Group PLC

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree Emis Group PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)   Date position held/dealing undertaken:        For an opening position...

Continue reading

D3eSports Announces Supporting Partnership With United States Esports Federation (USEF)

Formation of elite amateur sim-driver program created in partnership Houston, TX, Aug. 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire —D3eSports, a StemGen company, (OTC: SGNI), today announced a supporting partnership with the United States Esports Federation (USeF). The USeF is the official governing body for esports in the USA and a member of the International eSports Federation (IeSF). The national esports team, USA Esport™, have formed an elite amateur sim-driving unit, referred to as a Driver Task Force (DriverTF). The sanctioning body and the national team are now developing a qualifying process for United States citizens to compete for five driver seats as teammates on the official sim-racing esports team. As part of the partnership, USeF will utilize D3eSports as a recruiting partner for their new DriverTF game.  D3eSports...

Continue reading

Saga Communications, Inc. Reports 2nd Quarter 2022 Results

GROSSE POINTE FARMS, Mich., Aug. 05, 2022 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) reported today that net revenue increased 6.3% to $29.8 million for the quarter ended June 30, 2022 compared to $28.0 million for the same period last year. Station operating expense increased 3.7% for the quarter to $21.8 million compared to the same period last year. For the quarter, station operating income increased 10.6% to $9.3 million and operating income was $5.4 million compared to $4.6 million for the same quarter last year. Free cash flow was $3.2 million for the quarter compared to $4.2 million for the same period last year. Capital expenditures for the quarter were $2.6 million compared to $921 thousand for the same period last year. Capital expenditures for the quarter included the $1.1 million purchase of a...

Continue reading

Castellum, Inc. Announces Record Quarterly Revenue

Castellum, Inc. Announces Record Quarterly Revenue Revenue for Q2 2022 was approximately $11 million – Castellum, Inc. (OTC: ONOV) – https://castellumus.com/POTOMAC, Md., Aug. 05, 2022 (GLOBE NEWSWIRE) — Castellum, Inc. (OTC: ONOV) announces that it has achieved record revenue for its second quarter ended June 30, 2022. Revenue for Q2 2022 was approximately $11 million. Full financial results for Q2 2022 will be published on or about August 15, 2022, on www.otcmarkets.com. “We are very pleased with our record quarterly revenue,” said Mark Fuller, President and CEO of Castellum. “Our recent acquisition of Lexington Solutions Group added to our prior revenue base and now provides a solid platform for future Castellum growth. We anticipate a very busy next 90 days.” About Castellum, Inc.: Castellum, Inc. (OTC: ONOV)...

Continue reading

Cellectar Reports Financial Results for Second Quarter 2022

FLORHAM PARK, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2022. “During the second quarter, iopofosine passed an important milestone as an independent data monitoring committee completed a futility/efficacy assessment and unanimously recommended continuation of our pivotal Phase 2B trial in Waldenstrom’s macroglobulinemia (WM),” said James Caruso, president and CEO of Cellectar. “This global trial includes participation from leading institutions and world-renowned WM thought leadership, and we are excited by the active engagement of our investigators.” Mr. Caruso continued, “We also look...

Continue reading

Nathan’s Famous, Inc. Reports First Quarter Results and Declares Quarterly Cash Dividend of $0.45 Per Share

JERICHO, N.Y., Aug. 05, 2022 (GLOBE NEWSWIRE) — Nathan’s Famous, Inc. (“Nathan’s”, the “Company”, “we”, “us” or “our”) (NASDAQ:NATH) today reported results for its first fiscal quarter ended June 26, 2022. For the thirteen-week period ended June 26, 2022 (“first quarter fiscal 2023”):Revenues were $39,720,000, as compared to $31,319,000 during the thirteen weeks ended June 27, 2021; Income from operations was $11,780,000, as compared to $10,702,000 during the thirteen weeks ended June 27, 2021; Adjusted EBITDA1, a non-GAAP financial measure, was $12,065,000, as compared to $11,061,000 during the thirteen weeks ended June 27, 2021; Income before provision for income taxes was $9,880,000, as compared to $8,104,000 during the thirteen weeks ended June 27, 2021; Net income was $7,137,000, as compared to $5,763,000 during the...

Continue reading

Patriot Reports Second Quarter 2022 Net Income of $1.3 million; continued growth in loans and deposits

STAMFORD, Conn., Aug. 05, 2022 (GLOBE NEWSWIRE) — Patriot National Bancorp, Inc. (“Patriot,” “Bancorp” or the “Company”) (NASDAQ: PNBK), the parent company of Patriot Bank, N.A. (the “Bank”), today announced net income of $1.3 million, or $0.32 basic and diluted earnings per share for the quarter ended June 30, 2022, compared to $800,000, or $0.20 per basic and diluted earnings per share for the first quarter of 2022 and net income of $1.0 million, or $0.26 basic and diluted earnings per share reported in the second quarter of 2021. The 2021 second quarter included the benefit of a non-recurring employee retention tax credit (“ERC”) of $1.1 million. For the six months ended June 30, 2022, net income was $2.1 million, or $0.52 basic and diluted earnings per share, compared to a net income of $1.9 million, or $0.48 basic and $0.47...

Continue reading

Perma-Fix Reports Over 20% Increase in Revenue to $19.5 Million for the Second Quarter of 2022

Reports sequential and year-over-year revenue growth in both the Treatment and Services Segments ATLANTA, Aug. 05, 2022 (GLOBE NEWSWIRE) — Perma-Fix Environmental Services, Inc. (NASDAQ: PESI) (the “Company”) today announced financial results and provided a business update for the second quarter ended June 30, 2022. Mark Duff, President and CEO of the Company, commented, “We achieved a 20.5% increase in revenue to $19.5 million and a 198.6% increase in gross profit for the second quarter of 2022, compared to the same period last year. Importantly, for the second quarter of 2022, we achieved sequential and year-over-year revenue growth in both our Treatment and Services Segments. This growth was due in part to the resumption of work and attaining complete operational levels on several projects within our Services Segment, which...

Continue reading

Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “Candel remains on track to achieve several milestones in the second half of 2022,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “We are encouraged by the initial phase 2 clinical trial data for CAN-2409 in non-small cell lung cancer presented in June at ASCO. The data presented at ASCO showed an 87.5 percent disease control rate in heavily pretreated patients whose cancer was progressing on PD-1 agents at clinical trial entry. In the second...

Continue reading

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023 NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in the Clinical Program NXP900 IND-Enabling Work Progressing as Planned, Expected Completion by Year-End 2022 Recently Completed Private Placement Extends Cash Runway into H2 2024FORT LEE, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of novel therapies for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the second quarter of 2022 and provided an update on recent business progress. “Nuvectis has made excellent progress this year towards...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.